StockData

Eli Lilly vs Novo Nordisk A S

LLY and NVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LLY and NVO compare

Eli Lilly grew revenue faster over the last twelve months (45.5% versus 6.4% for Novo Nordisk A S).

Eli Lilly pays a dividend yielding 0.37%; Novo Nordisk A S does not pay one.

Eli Lilly scores higher on the StockData Score (19 against 4 for Novo Nordisk A S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLLYNVO
Size and price
Market cap$1.3T–
Share price$1415.55$40.70
Change, 1 year38.1%−15.7%
Change, 5 years444%−24.7%
Beta (5Y)0.280.76
Employees50K70K
StockData Score
Total score19 (better)4
Valuation score2 (better)0
Growth score5 (better)2
Performance score5 (better)0
Health score4 (better)2
Dividend score3 (better)0
Valuation
P/E45.9×–
P/S15.4×–
P/B33.1×–
EV/EBITDA37.3×–
PEG0.93–
Fair value$1131.93–
Margin of safety−25.1%–
Growth
Revenue growth (TTM)45.5% (better)6.4%
Revenue growth, 5Y average21.6% (better)19.5%
Net income growth (TTM)49.8%–
EPS growth (TTM)50.7% (better)1.8%
EPS growth, 5Y average27.6% (better)20.7%
Profitability
Gross margin83.6% (better)81.0%
Operating margin–41.3%
Net margin31.9%–
FCF margin–19.1%
Return on equity86.1%–
Financial health
Debt / equity1.23–
Net debt / EBITDA1.210.82 (better)
Interest coverage–18.8×
Current ratio1.39 (better)0.80
Altman Z-score8.50–
Piotroski F-score7–
Dividends and buybacks
Dividend yield0.37%–
Payout ratio21.7%–
Years of dividend growth9–
Dividend growth, 5Y average15.2%–
Buyback yield0.44%–
Shareholder yield0.81%–
Ownership
Held by institutions83.8%7.3%
Held by insiders10.4%0.00%
Insider net buying, 12 months−$373M–
Superinvestors holding3 (better)1
Short interest, % of float0.86%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.